PDF Archive search engine
Last database update: 01 October at 03:37 - Around 220000 files indexed.
Results for «trastuzumab»:
Total: 13 results - 0.034 seconds
cvfile 0023229 100%
sponsored by MSD, 2012, Principal investigator[MK8669-064] -2- - Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment, IIT, 2012, Sub-investigator [LV] - A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation, sponsored by Novartis, 2012, Sub-investigator[BELLE4] - An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer, sponsored by Boehringer Ingelheim, 2012, Sub-investigator[BIBW1200.89] - A phase III prospective, 2-cohort, non-randomized, multi-center, multinational, open label study to assess the safety of assisted-and self-administered subcutaneous trastuzumab ad adjuvant therapy in patients with operable HER2-positive early breast cancer, sponsored by ROCHE, 2012, sub-investigator[SafeHer] - A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer, sponsored by Roche, 2011, Sub-investigator[APHINITY] - Phase III multicenter Randomized Open-label study of irinotecan plus CapEcitabine versus capEcitabine in patients previously treateD with anthracycline and taxane for HER2 negative metastatic breast cancer, IIT, 2011, Principal investigator [PROCEED] - A phase III randomized, multicenter, 2-arm, open-label trial to evaluate the efficacy of T-DM1 compared with treatment of physician’s choice in patients with HER2-positive metastatic breast cancer who have received at least 2 prior regimens of HER2-directed therapy, sponsored by Roche, 2011, Sub-investigator[THERESA] - A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as 1st-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer (MBC) who have received trastuzumab and endocrine therapy in the neoadjuvant and/or adjuvant setting, sponsored by GSK, 2011, Sub-investigator[EGF114299] - A randomized, Double-Bline, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence, sponsored by Amgen, 2011, sub-investigator[D-CARE] - A phase II trial of NEoadjuvant bevAcizumab, docetaxel and carboplatin for Triple negative breast cancer(NEAT trial).
HER2/neu ph2 ADC Therapeutics CD19 ph2 relapsed or refractory DLBCL ADC Therapeutics CD25 ph2 Hodgkin lymphoma AbbVie c-met ph2 NSCLC 6SK BCMA ph2 Multiple myeloma Roche LIV1 Ph1/2 Triple Negative Breast Cancer(TNBC) Daiichi Sankyo HER3 Ph1/2 BMS-986148 BMS mesothelin Ph1/2 solid tumor enapotamab Seattle Genetics AXL Ph1/2 solid tumor mirvetuximab soravtansine trastuzumab duocarmazine trastuzumab Bio-Thera maytansine Solutions anetumab ravtansine tisotumab vedotin Remegen RC48 loncsstuximab tesirine camidanlumab tesirine telisotuzumab vedotin belantamab mafodotin ladiratuzumab vedotin patritumab deruxtecan HER2 positive metastatic breast cancer HER2 positive metastatic breast cancer pancreatic cancer ovarian cancer HER2 positive metastatic breast cancer HER3 positive metastatic breast cancer https://www.biochempeg.com Biochempeg Scientific Inc.
The report segments the global biosimilar monoclonal antibodies market by drug class and by application.The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab.
Application Segment Analysis Trastuzumab Ankylosing Spondylitis Tumor Rheumatoid Arthrtis Cardiovascular Reasons for Buying this Report:
Rising stars against Her2-positive solid tumors Enhertu's original research company is Daiichi Sankyo, which is an ADC composed of trastuzumab and ixiticon derivatives.
As two more options came onto the market - Docetaxel, also in 2002, and Trastuzumab, in 2007 - list prices rose to $2488 and $5300 respectively.
Anti-Cancer Missile ADC Drugs 3 Design Elements 5 Approved Drugs Multiple Clinical Trialsadc drugs 45%
①brentuximab vedotin, ②ado-trastuzumab emtansine (T-DM1), ③inotuzumab ozogamicin, ④gemtuzumab ozogamicin ⑤polatuzumab vedotin-pii.
Antibody drug1 38%
Current Status and Market Currently, there are two US FDA approved ADCs available - Adcetris (brentuximab vedotin) and Kadcyla “The concept of ADC is not new and (ado-trastuzumab emtansine).
Drug Gene(s) Drug Gene(s) Clopidogrel (Plavix®) CYP2C19 Azathiopurine (Imuran®) TPMT Atomoxetine (Strattera®) CYP2D6 Irinotecan (Camptosar®) UGT1A1 Codeine CYP2D6 Cetuximab (Erbitux®)* EGFR Tamoxifen (Nolvadex®) CYP2D6 Erlotinib (Tarceva®)* EGFR Warfarin (Coumadin®) CYP2C9, VKORC1 Imatinib mesylate (Gleevec®)* C-KIT Abacavir (Ziagen®) HLA-B*5701 Panitumumab (Vectibix®)* KRAS Carbamazepine (Tegretol®) HLA-B*1502 Trastuzumab (Herceptin®)* Her2/neu * Response to these drugs is dependent on genetic variations that are present in tumor tissue.
A randomized, controlled, open label study to evaluate the efficacy and safety of Herceptin® (trastuzumab) in combination with the oral aromatase inhibitor Arimidex® (anastrozole) compared with Arimidex® alone as first and second line treatment administered to postmenopausal, hormone receptor positive (ER+ve and/or PR+ve) patients with HER2 overexpressing metastatic breast cancer, sponsored by Roche.
Meyer, Firenze, ITALY, Firenze, IT 12:00 - 12:00 7P - Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: